News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 73–84 of 243 stories

Bicycle Therapeutics Wins FDA Orphan Drug Status for Nuzefatide in Pancreatic Cancer

Bicycle Therapeutics disclosed with its Q3 results that the FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer in September. The EphA2-targeting Bicycle Drug Conjugate is in a Phase 2 trial in recurrent pancreatic ductal adenocarcinoma, with further updates expected in 2027. The designation is a regulatory status, not an approval.

Hikma Launches NPH Otic Solution in US with Orbicular Partnership

Hikma Pharmaceuticals has launched a sterile generic ear-drop treatment containing neomycin, polymyxin B and hydrocortisone in the United States. The product was developed by Orbicular Pharmaceutical Technologies, which holds the abbreviated new drug application, while Hikma will commercialise and distribute it. The medicine has FDA approval as a Competitive Generic Therapy for certain bacterial infections of the external ear. The announcement does not establish UK marketing approval.

Virax Biolabs Appoints Three China Distributors for ImmuneSelect

Virax Biolabs has signed three non-exclusive distribution agreements in mainland China for its ImmuneSelect research-use immune profiling products. The agreements, made through its Shanghai subsidiary, involve AmyJet Scientific, Jiangsu Real-Gen Biotechnology and Zhixi Biotechnology. They expand Virax's distributor-led commercial network following initial Chinese product sales. ImmuneSelect is for research use only and is distinct from the company's in-development ViraxImmune diagnostic platform.

Codis Begins Construction of PSD-4 Spray-Drying Facility in Haverhill

Codis has completed demolition work and begun construction of a PSD-4 spray-drying facility at its Haverhill manufacturing site. The investment will add solvent-capable commercial-scale capacity for amorphous solid dispersions, complementing the company's existing PSD-2 equipment and formulation services in Nottingham. Codis expects the new capacity to become available in the final quarter of 2027, subject to installation and validation.

Nxera Exercises Option on Idorsia's Fabry Drug Lucerastat for Asia-Pacific

Nxera Pharma has exercised its option to license lucerastat, Idorsia's oral Phase 3 therapy for Fabry disease, and signed a co-development and commercialisation agreement. It gains rights in Japan, South Korea, Taiwan and selected other Asia-Pacific markets, excluding China, and pays CHF 7 million upfront. Idorsia is eligible for royalties on net sales in the territory.

SenzaGen Completes £2.12m Acquisition of Newcastle Spinout Alcyomics

Swedish non-animal testing company SenzaGen completed its acquisition of Newcastle-based Alcyomics on 5 November 2026, following an agreement announced on 28 October. SenzaGen paid approximately £2.12 million in cash for all shares, with up to a further £1.88 million payable through conditional earn-outs. Alcyomics provides human-based preclinical immunotoxicology testing for drug development, including its Skimune platform for assessing immune reactions to biological medicines.

Cell Guidance Systems Launches Automated EVlution Pro TFF Systems

Cell Guidance Systems has launched EVlution Pro, a benchtop tangential-flow filtration system for concentrating and exchanging buffers in samples containing extracellular vesicles, proteins and other biomolecules. Two models are available: Pro 1 provides basic monitoring, while Pro 3 adds balances, pressure and temperature sensors with automated data logging. Orders are open. The launch extends its existing EVlution cartridge range rather than introducing filtration technology for the first time.

Purespring Presents Preclinical PS-003 Data in X-Linked Alport Syndrome, Targets 2027 IND

Purespring Therapeutics has presented preclinical data at ASN Kidney Week 2026 showing that a single dose of its kidney-targeted gene therapy PS-003 produced durable COL4A5 expression in a mouse model of X-linked Alport syndrome, with no treatment-related safety concerns in minipigs. The company plans to file an IND in 2027.